Uppsala, Sweden 8/31/16—Separations technologies firm Biotage has made a DKK 15 million ($2.2 million = DKK 6.67 = $1) investment in Chreto Aps, acquiring a 22% stake in the company, with an option to acquire all outstanding shares until December 31, 2018, for DKK 600 ($90) per share. Chreto Aps is a developer of single-use protein purification technology for biomanufacturing based on recombinant Dual Affinity Protein molecules.

Chreto Aps’ single-use kit contains a Dual Affinity Protein for attachment to the target protein, a membrane device, buffers, assays and ancillaries. The technology was originally developed by Novozymes.